RNA therapeutics

Genflow Biosciences appoints seasoned biotech leader Gad Berdugo as Chairman to accelerate its gene therapy pipeline for age-related diseases. Berdugo’s expertise in RNA-LNP therapeutics and U.S. market expansion is expected to drive strategic growth. Key data readouts in 2026 will be critical under his guidance, with Tamara Joseph continuing on the board for continuity.

Novartis intends to acquire Avidity Biosciences for $12 billion, a 46% premium, focusing on Avidity’s neuroscience pipeline and Antibody Oligonucleotide Conjugates (AOCs™) platform enabling targeted RNA delivery. The deal hinges on spinning off Avidity’s cardiology programs into “SpinCo,” capitalized with $270 million. Novartis gains access to late-stage clinical programs for Duchenne muscular dystrophy, myotonic dystrophy, and facioscapulohumeral muscular dystrophy, aligning with its neuroscience portfolio. SpinCo will advance cardiology-focused AOC programs and existing collaborations. The acquisition awaits regulatory approval.